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Glomerular complement regulation is overwhelmed in passive Heymann nephritis is a rat model of immune complex
Heymann nephritis. glomerular disease that closely resembles human mem-
Background. An injection of anti-Fx1A antibodies in rats branous nephropathy [1, 2]. The passive form of thisleads to passive Heymann nephritis (PHN), a model of mem-
model [passive Heymann nephritis (PHN)] is inducedbranous nephropathy. Fx1A is a crude extract of renal cortex
by an injection of heterologous anti-Fx1A antibodies,that contains megalin as a principal component. However, when
rats are given anti-megalin antibodies, abnormal proteinuria which are raised against rat proximal tubule brush-border
does not occur. Because of the established complement depen- antigens. Within five days of anti-Fx1A injection, abnor-
dence of PHN, we hypothesized that antibodies neutralizing mal proteinuria occurs. Histologically, there is progres-complement regulatory proteins in the rat glomerulus also were
sive accumulation of heterologous IgG in subepithelialrequired to induce PHN. Two likely targets are Crry and CD59,
immune deposits, which is accompanied by podocyteproteins abundant on the rat podocyte and contained within
Fx1A that inhibit the C3 convertase and C5b-9 assembly, re- effacement and a conspicuous lack of inflammatory cells.
spectively. C3 and the C5b-9 membrane attack complex are invari-
Methods. Rats were injected with anti-megalin monoclonal ably present in a distribution similar to heterologousantibodies, followed by anti-Crry and/or anti-CD59 F(ab)2 anti- IgG, providing circumstantial evidence that IgG in thebodies five days later. In a second group of experiments, rats
immune complexes activates complement [3, 4]. In stud-were injected with anti-Fx1A or anti-Fx1A immunodepleted
of reactivity against Crry and/or CD59. ies in which complement was depleted, abnormal pro-
Results. In the setting of podocyte-associated anti-megalin teinuria was completely prevented, confirming a role for
monoclonal antibodies, simultaneous neutralization of Crry complement activation in PHN [5–8].and CD59 function led to the development of significant pro-
Considerable effort has been expended in elucidatingteinuria (11.0  2.1 mg/day, P  0.001 vs. all other groups).
the antigenic targets in Heymann nephritis. One necessaryIn contrast, animals that had neither or only one of these comple-
ment regulators inhibited had normal urinary protein excretion antigen is the protein originally termed gp330, and now
(6 mg/day). In animals given anti-Fx1A depleted of anti-Crry known as megalin, that is present on both the proximal
and/or anti-CD59, all groups developed typical PHN, charac- tubule brush border and the podocyte surface [9–12].terized by heavy proteinuria and extensive glomerular deposi-
Thus, in active Heymann nephritis (AHN), when mega-tion of C3 and C5b-9.
lin is removed from Fx1A, immune glomerular stainingConclusion. Crry and CD59 play an important role in re-
straining complement-mediated injury following subepithelial for IgG is absent [9]. However, induction of AHN with
immune complex deposition; however, in PHN, their regula- megalin alone, or PHN with anti-megalin alone, yields
tory capacity is overwhelmed. subepithelial immune deposits identical to that seen in
classic HN, but without complement deposition or devel-
opment of proteinuria [13, 14]. Therefore, additional anti-
gens targeted by anti-Fx1A are necessary for complement
fixation, podocyte injury, and proteinuria to occur. An
injection of single monoclonal antibodies directed againstKey words: Crry protein, CD59 protein, Fx1A, megalin, membranous
megalin does not persist long in the glomerulus [15, 16]nephropathy, immune complex glomerular disease, proteinuria, podo-
cyte injury. and is presumably endocytosed and catabolized, along
with their target protein [17]. In contrast, polyclonal anti-Received for publication January 11, 2001
bodies, especially when directed against multiple antigens,and in revised form March 12, 2001
Accepted for publication March 15, 2001 lead to capping of their target proteins on the podocyte
surface [18], followed by shedding of immune complexes, 2001 by the International Society of Nephrology
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which persist in the subepithelial space [19]. Similarly, an provided by Dr. Donna Mendrick (Gene Logic, Inc.,
injection of a mixture of different monoclonal antibodies Gaithersburg, MD, USA) [31]. Hybridomas were grown
against megalin results in the persistence of the mono- in Dulbecco’s modified Eagle’s medium (DMEM)/10%
clonal antibodies in situ, as seen by granular staining for newborn calf serum in shaker flask culture. IgG was
IgG in the glomerular capillary by immunofluorescence purified from the supernatant by ammonium sulfate pre-
(IF) microscopy, presumably as a result of cross-linking cipitation followed by protein G affinity chromatography
and aggregate formation of the megalin/anti-megalin (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
complexes [20]. The IgG was concentrated by Centriprep centrifugation
The complement cascade is subject to regulation at (Millipore, Bedford, MA, USA) and dialyzed into 150
multiple points by various endogenous proteins. Two mmol/L NaCl. Reactivity against megalin was confirmed
important complement regulators in rodents include by indirect IF on normal rat kidney cryostat sections
Crry (CR1-related gene y protein product), a transmem- using serial dilutions of each of these monoclonal anti-
brane protein that inhibits both an alternative and classic bodies. The two monoclonal antibodies showed equiva-
pathway C3 convertase activity [21, 22], and CD59, a lent staining of proximal tubular brush border, positive
glycosylphosphatidyl inositol-linked protein that inhibits at concentrations 3 g/mL.
assembly of C5b-9 [23]. These proteins are expressed in
a variety of tissues, including the glomerulus [24, 25]. Fur- Antibodies to Crry and CD59
thermore, Crry and CD59 are expressed on renal podo-
Recombinant soluble rat Crry and CD59 (rCrry andcytes and have been shown to protect against antibody-
rCD59) were expressed in Pichia pastoris, as previouslydirected complement-mediated cytotoxicity in vitro [26].
described [32, 33]. rCD59 was purified by affinity chro-Given that Crry is present in the proximal tubule
matography on a column of 6D1, a monoclonal antibody[24, 27], we hypothesized that autoantibodies neutralizing
to rat CD59, bound to CNBr-activated-Sepharose (Amer-Crry function might be raised in AHN and contribute to
sham Pharmacia Biotech) [33]. rCrry was purified bythe pathogenesis of this disease. This was confirmed in a
sequential Mono Q and Mono P chromatography [32].study showing that animals immunized with Fx1A lacking
Purity was confirmed by sodium dodecyl sulfate-poly-Crry had little glomerular C3 deposition and normal uri-
acrylamide gel electrophoresis (SDS-PAGE). Antibod-nary protein excretion, despite the characteristic glomeru-
ies to purified rCrry and rCD59 were raised in sheep.lar deposits of rat IgG [28]. Furthermore, the administra-
IgG was purified from sera by ammonium sulfate precipi-tion of anti-Crry antibodies led to C3 deposition and heavy
tation followed by protein G affinity chromatography.proteinuria, as did reconstitution of the original immuno-
gen with recombinant Crry. Based on these data, we con- IgG was converted to F(ab)2 by pepsin digestion and
cluded that in AHN, autoantibodies directed against Crry purified by size-exclusion chromatography as previously
were necessary to allow complement activation to proceed described [28]. F(ab)2 antibodies were concentrated to
and cause podocyte injury and proteinuria [28]. approximately 10 mg/mL and dialyzed into 150 mmol/L
In addition to Crry, CD59 is present in proximal tubular NaCl. Preimmune sheep F(ab)2 were prepared in an
cells [24, 29]. As a result, heterologous antiserum raised analogous fashion.
against Fx1A includes antibodies directed against Crry Strong reactivity of these F(ab)2 antibodies to rCrry or
and CD59, which nullify their complement regulatory ac- rCD59 was confirmed by enzyme-linked immunosorbent
tivity in vitro [26, 30]. Given these observations and our assay (ELISA). Furthermore, functional inhibition was
results in the AHN model, our current study hypothesized proven by a complement-mediated hemolytic assay, as
that in PHN, anti-Crry and anti-CD59 antibodies in anti- described by Takizawa, Okada and Okada [34]. In brief,
Fx1A neutralize their respective complement inhibitors. blood was obtained from normal rats via cardiac punc-
This allows podocyte-associated anti-Fx1A to activate com- ture and washed three times with GVB-Mg-EGTA
plement, and leads to the formation of C5b-9, podocyte buffer [130 mmol/L NaCl, 10 mmol/L Na barbital, pH
injury, and proteinuria. Two questions were addressed in 7.4, 0.1% gelatin, 10 mmol/L egtazic acid (EGTA), and
these studies. First, does normal complement regulation
2 mmol/L MgCl2]. A 50% suspension of red blood cellsprevent podocyte injury in the setting of subepithelial
(RBCs) in phosphate-buffered saline (PBS) was incu-anti-megalin immune deposits? Second, does neutraliza-
bated with an equal volume of 36 g/mL neuraminidasetion of Crry and/or CD59 activity by anti-Fx1A contrib-
(Sigma, St. Louis, MO, USA) at 37C for one hour.ute to complement activation and the development of
RBCs were washed again in buffer and adjusted to adisease in PHN?
concentration of 108 cells/mL. Fifty microliters of this
suspension were incubated with 50L of various concen-
METHODS trations of the previously mentioned F(ab)2 antibodies
Monoclonal antibodies in buffer for 30 minutes at room temperature. Thereaf-
ter, 100 L of 60% normal rat serum were added toMouse anti-gp330/megalin monoclonal antibodies K57/27
and K35/9, both of the IgG2a subclass, were generously each sample, followed by shaking for one hour at 37C.
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To stop the reaction, 1.0 mL of cold PBS was added to Western blot
each sample. Each sample was centrifuged at 2500 rpm rCrry or rCD59 (0.5 g) were electrophoresed under
for five minutes, and the OD414 was determined to assess nonreducing conditions, followed by electrophoretic
the degree of hemoglobin release. The OD414 of control transfer to an Immobilon-P nitrocellulose membrane
RBCs lysed in distilled water was defined as 100% hemo- (Millipore). After blocking in 5% milk/TBST overnight,
lysis. Murine monoclonal antibody 5I2 (Pharmingen, San lanes were cut apart and separately incubated for 1.5
Diego, CA, USA), which binds and neutralizes rat Crry hours in each of the immunodepleted anti-Fx1A frac-
[34], and antibody 6D1 were used as the positive controls. tions, as well as preimmune sheep IgG, at 12.5 g/mL
in TBST. The lanes were then washed in TBST andPreparation of anti-Fx1A
incubated in HRP-conjugated anti-sheep IgG at a 1:2000
Fx1A was prepared from freshly isolated normal dilution in TBST for 1.5 hours. Thereafter, strips were
Sprague-Dawley rat kidneys by standard techniques washed in TBST and developed using an enhanced
[28, 35] and was used to immunize sheep. The capacity of chemiluminescence (ECL) reagent (Amersham Phar-
anti-Fx1A to induce PHN was tested, and nephritogenic macia Biotech).
antisera from a single sheep were used in these studies.
Nephritogenic IgG was purified from this anti-Fx1A anti- Experimental protocols
serum by protein G affinity chromatography. Anti-Fx1A This research using rats was approved by the Univer-
IgG was concentrated to approximately 15 mg/mL and sity of Chicago Animal Care and Use Committee and
dialyzed into150 mmol/L NaCl. Preliminary experiments was performed in accord with the NIH Guide for the
showed that 15 mg was an adequate dose to produce 65 Care and Use of Laboratory Animals. All antibodies
10 mg/day of urinary protein at day 5 (N  10). were injected intravenously into normal 300 g male
Sprague-Dawley rats. Rats were anesthetized via contin-Immunodepletion of anti-Fx1A
uous isoflurane/oxygen inhalation for injections and for
To produce affinity columns, 25 mg each of rat rCrry
harvest of tissue prior to sacrifice. Two separate experi-
and rCD59 were separately coupled to CNBr-activated
ments were performed. The first was designed to exam-Sepharose (Amersham Pharmacia Biotech). Anti-Fx1A
ine events occurring when complement regulators areIgG was brought to 0.5 mol/L NaCl and then applied to
neutralized in the setting of podocyte-associated anti-each of the two columns in 4 mL increments. A portion
megalin antibodies. The second was designed to deter-of the anti-Fx1A immunodepleted of anti-Crry was then
mine the role of anti-Crry and anti-CD59 reactivity inapplied to the rCD59 column to deplete anti-CD59 reac-
anti-Fx1A.tivity. As a control for any effect of Sepharose, anti-Fx1A
To evaluate the time course of anti-megalin mono-was applied to a bovine serum albumin (BSA)-Sepha-
clonal antibody accumulation in glomeruli, 10 mg eachrose column [36]. Each pass through was concentrated to
of K57/27 and K35/9 were injected intravenously. Serialapproximately 15 mg/mL and dialyzed into 150 mmol/L
evaluation of biopsy specimens demonstrated maximalNaCl. ELISA confirmed the removal of reactivity against
glomerular staining for mouse IgG five days followingCrry and CD59, which was further confirmed by immuno-
injection; thus, this time point was chosen for subsequentblotting. To verify that the processing of the various frac-
evaluation of Crry and CD59 function, as follows.tions did not affect their reactivity to Fx1A, indirect IF
Rats were divided into seven groups. In four experi-was performed using serial dilutions of each of these four
mental groups, rats were injected intravenously with 15fractions to stain normal rat kidney cryostat sections. Proxi-
mg each of K57/27 and K35/9. Five days after injection,mal tubule brush-border staining was present to an equiva-
rats were injected with 5 mg anti-Crry and/or 5 mg anti-lent degree in all four fractions (positive 1 g/mL).
CD59 F(ab)2, or preimmune F(ab)2 as a control. As
ELISA controls, three additional groups received no K57/27 or
K35/9, but received 5 mg of anti-Crry F(ab)2 and/orMultiwell plates (Fisher Scientific, Pittsburgh, PA,
anti-CD59 F(ab)2. Animals were placed in metabolicUSA) were coated with 300 ng/mL of rCrry or rCD59
cages for an 18-hour urine collection beginning 24 hoursin pH 9.6 sodium carbonate buffer for two hours, blocked
after F(ab)2 injection and were sacrificed thereafter forwith 1% BSA/PBST for one hour, and then incubated
collection of blood and kidney tissue.with various antibodies in PBST for two hours. 5I2 and
To determine whether anti-Fx1A neutralized Crry6D1 were used as positive controls. Plates were then incu-
and/or CD59 activity in PHN, the following studies werebated with horseradish peroxidase (HRP)-conjugated rab-
done. Four groups were studied that received differentbit anti-sheep IgG or HRP-conjugated sheep anti-mouse
preparations of immunodepleted anti-Fx1A IgG, at a doseIgG (Jackson Immunoresearch, Bar Harbor, ME, USA)
of 15 mg per animal: group A, control-depleted anti-for two hours, followed by detection with o-phenylenedi-
amine reagent (Sigma) at 450 nm. Fx1A; group B, anti-Fx1A depleted of anti-Crry; group
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Table 1. Effects of anti-Crry and anti-CD59 onC, anti-Fx1A depleted of anti-CD59; and group D, anti-
complement-mediated hemolysis
Fx1A depleted of both anti-Crry and anti-CD59. On day
Hemolysis5, rats were placed in metabolic cages, and urine was
Crry inhibitor CD59 inhibitor %collected over an 18-hour period. Rats were then euthan-
5I2 — 0ized, with blood and tissue harvested as noted previously
Anti-Crry F(ab)2 — 6.3in this article. — 6D1 0
— Anti-CD59 F(ab)2 72.5
Urinary protein determination 5I2 6D1 7.6
Anti-Crry F(ab)2 6D1 52.8Urinary protein was measured by the sulfosalicylic
5I2 Anti-CD59 F(ab)2 87.2acid method. Proteinuria was considered abnormal when Anti-Crry F(ab)2 Anti-CD59 F(ab)2 89.6
excretion was 6 mg/day [28]. In experiments in which
Monoclonal antibodies 5I2 and 6D1 were used as positive controls. Polyclonal
F(ab)2 had been injected, urine was evaluated by non- F(ab)2 antibodies were used at a concentration of 400 g/mL, and monoclonal
antibodies at a concentration of 20 g/mL.reducing SDS-PAGE stained with Coomassie blue to
evaluate whether F(ab)2 appeared in urine. To normal-
ize data, the volume of urine that contained 10 g creati-
nine was electrophoresed in each lane. in minor hemolysis above background. In contrast, the
polyclonal antibodies effectively inhibited complementTissue processing
regulation leading to marked hemolysis. This was partic-
Cryostat sections of 4 m thickness were air dried, ularly true of anti-CD59 F(ab)2. The addition of mono-fixed in ether/ethanol, blocked with dilute horse serum, clonal or polyclonal anti-Crry antibodies to anti-CD59
and stained for sheep or mouse IgG, rat C3 (Cappel F(ab)2 resulted in nearly complete hemolysis, indicatingOrganon Teknika Corp., Durham, NC, USA), and hu- considerable synergism when both C3 convertase activity
man C3d (Dako, Carpinteria, CA, USA) by direct IF. and C5b-9 assembly were left uninhibited.
The anti-rat C3 antibodies detect C3c and not C3d, while
the anti-human C3d antibodies react with rat C3d [37]. Effects of inhibiting podocyte Crry and CD59 in the
C5b-9 was detected by indirect IF with monoclonal anti- setting of subepithelial immune deposits
body 2A1 (a gift of Dr. William Couser, University of
Pilot studies showed that simultaneous injection of theWashington, Seattle, WA, USA). In experiments involv-
two anti-megalin monoclonal antibodies did not resulting the administration of murine monoclonal antibodies,
in proteinuria (3.8 0.4 mg/day on day 5). One explana-C5b-9 was detected with biotin-conjugated 2A1, fol-
tion for this finding is that normal intrinsic complementlowed by streptavidin-HRP (Vector Labs, Burlingame,
regulation limits activation of complement. To addressCA, USA). Sections were scored for glomerular capillary
this, neutralization of podocyte complement regulationstaining on a scale of 0 to 4	 by an observer blinded to
with anti-Crry and anti-CD59 F(ab)2 antibodies wasthe origin of the slides [38].
used because these smaller fragments have more ready
access to the subepithelial site of immune complex for-Statistics
mation [39], and they cannot independently activateAll data are expressed as mean  SEM. Comparisons
complement. As shown in Figure 1, proteinuria devel-between groups were done by analysis of variance with
oped in the group receiving anti-Crry and anti-CD59Tukey’s pair-wise comparisons. A difference was consid-
F(ab)2 together (11.0 mg  2.1 mg/day), which was sta-ered statistically different when the P value was 0.05.
tistically greater (P 0.001) than all of the other groups,Statistical computations were performed with Minitab
every one of which had normal urinary protein excretion.software (State College, PA, USA).
Thus, inhibition of Crry and CD59 can lead to podocyte
damage and proteinuria in the setting of podocyte-associ-
RESULTS ated IgG.
Functional inhibition by anti-Crry and Although the control group receiving anti-Crry and
anti-CD59 antibodies anti-CD59 F(ab)2 alone did not have abnormal protein-
uria, and previous studies have shown that even afterAnti-Crry and anti-CD59 F(ab)2 had strong reactivity
high dose F(ab)2 injection, urinary protein excretion iswith their respective antigens by ELISA (data not shown)
not increased [39], it was important to verify that theand also inhibited Crry and CD59 function, as shown by
increased proteinuria in rats from group 4 was from athe results of the complement-mediated hemolysis assay
glomerular source. This was confirmed by nonreducing(Table 1). This assay measures hemolysis of rat RBCs
SDS-PAGE of urine, which showed that urinary proteinby the alternative pathway of complement. Interestingly,
was predominantly albumin and contained little to nomonoclonal antibodies 5I2 or 6D1 alone did not lead to
hemolysis, while the combination of the two did result appreciable F(ab)2 (Fig. 2).
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Fig. 1. Urinary protein excretion in the dif-
ferent groups receiving inhibitors of comple-
ment regulation. The first four groups received
the indicated F(ab)2 antibodies five days fol-
lowing injection of anti-megalin monoclonal
antibodies, whereas the three control groups
received only the indicated F(ab)2 antibodies.
Each data point represents an individual ani-
mal. The short horizontal bars represent the
group means. Urinary protein was considered
abnormal when6 mg/day (horizontal dashed
line). The group receiving anti-Crry and anti-
CD59 F(ab)2 antibodies after anti-megalin
monoclonal antibodies had elevated urinary
protein compared with all the other groups
(P  0.001).
cally different (Table 3). The presence of anti-megalin
monoclonal antibodies was associated with a greater
amount of C3 deposits, as C3c and C3d (P  0.05; Table
2), illustrating complement was activated by mouse anti-
megalin IgG at the level of C3 convertases even with
active Crry. By immunohistochemistry, C5b-9 was weakly
present in all groups at the time of sacrifice (Fig. 3D).
Nonetheless, the development of proteinuria in group IV
indicates that neutralization of Crry and CD59 function
allowed complement activation to C5b-9. The low levels
of C5b-9 staining could reflect prior shedding of C5b-9
[40] and/or that the technique is relatively insensitive to
biologically meaningful C5b-9.
Fig. 2. Urinary protein predominantly contained albumin, but not Depletion of anti-Crry and anti-CD59 reactivity
F(ab)2. Urine containing 10 g creatinine was electrophoresed under from anti-Fx1A
nonreducing conditions and stained with Coomassie blue. Group 4
animals received anti-megalin monoclonal antibodies followed by anti- Anti-Fx1A IgG showed reactivity against both rCrry
Crry and anti-CD59 F(ab)2, while group 7 animals received anti-Crry and rCD59 by ELISA and immunoblotting. Affinity col-
and anti-CD59 F(ab)2 alone. SDS-PAGE confirmed urinary protein umn chromatography was successful in completely re-data, showing that group 4 animals had increased proteinuria.
moving this reactivity (Fig. 4). By column chromatogra-
phy elution profiles, it was estimated that approximately
0.5% of the total anti-Fx1A IgG was directed against
Direct IF revealed granular staining for mouse IgG in each of Crry and CD59.
glomerular capillaries in a segmental distribution (Fig. In animals receiving undepleted anti-Fx1A or anti-
3A), with no differences between groups (Table 2). Stain- Fx1A depleted of anti-Crry and/or anti-CD59, mean val-
ing for sheep F(ab)2 in groups given anti-Crry and/or ues for proteinuria were statistically similar between all
anti-CD59 F(ab)2 showed trace amounts remaining at four groups (group A, 34.9  11.7; group B, 29.1  9.3;
the time of sacrifice, 42 hours after their injection (data group C, 29.8  13.5; and group D, 49.0  14.4 mg/
not shown). Although animals receiving antibodies to day). Figure 5 illustrates the individual data points. Thus,
the C3 convertase regulator Crry had slightly greater removal of anti-Crry and anti-CD59 reactivity from anti-
staining for C3c and C3d (Fig. 3 B, C) than animals not Fx1A did not affect the potential to cause proteinuria.
Strong granular staining for sheep IgG in the glomeru-receiving anti-Crry antibodies, these were not statisti-
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Fig. 3. Representative micrographs of animals
receiving mouse anti-megalin monoclonal anti-
bodies followed by anti-Crry F(ab)2. Animals
showed granular staining for mouse IgG as
depicted in (A). Staining for C3c was relatively
weak (B), but the stronger staining for the
C3 cleavage fragment C3d demonstrates prior
complement activation (C). Immunoperoxi-
dase-labeled indirect staining for C5b-9 was
also weak by the time of sacrifice (D).
Fig. 6. Representative micrographs of animals receiving immunodepleted anti-Fx1A. Direct immunofluorescence staining for sheep IgG (A), C3
(B), and C5b-9 (C) is shown. Staining for each component was statistically similar between all groups.
lar capillary tuft was observed by direct IF and was statis- C3c staining, but this trend did not reach statistical sig-
tically similar between all four groups. Note that the extent nificance (R  0.409, P  0.059). The IF staining results
of glomerular IgG deposition was markedly greater in the indicate the ability of anti-Fx1A to activate complement
PHN rats in comparison with the rats that received anti- was not dependent on neutralization of Crry and CD59
megalin monoclonal antibodies (Fig. 6A vs. Fig. 3A). activity.
C3c and C5b-9 were present in a similar distribution as
IgG and also were statistically similar between all four
DISCUSSIONgroups (Table 3 and Fig. 6). The extent of staining for all
Complement inhibition has been shown to have a pro-of these components showed relatively little variability.
Urinary protein excretion correlated with glomerular tective role in different forms of immune complex glo-
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Table 2. Glomerular staining following administration of anti-megalin monoclonal antibodies
Group Day 0 Day 5 Mouse IgG Rat C3c Rat C3d
1 K57/27 	 K35/9 Preimmune F(ab)2 1.70.8 0.90.2 1.80.3
2 K57/27 	 K35/9 Anti-Crry F(ab)2 2.00.7 1.50.3 2.50.2
3 K57/27 	 K35/9 Anti-CD59 F(ab)2 2.30.6 1.10.3 1.90.3
4 K57/27 	 K35/9 Anti-Crry F(ab)2 	 anti-CD59 F(ab)2 1.80.8 1.30.3 2.00.2
5 — Anti-Crry F(ab)2 — 0.30.1 0.50.1
6 — Anti-CD59 F(ab)2 — 0.10.1 0.50.1
7 — Anti-Crry F(ab)2 	 anti-CD59 F(ab)2 — 0.50.1 0.70.1
On day 1, K35/9 and K57/27 antimegalin monoclonal antibodies were injected at a dose of 15 mg each. On day 5, anti-Crry F(ab)2 and/or anti-CD59 F(ab)2 were
injected at a dose of 5 mg each. Semiquantitative immunofluorescence scores for mouse IgG, rat C3c and C3d are shown. There were no statistically significant
differences between any of the four groups receiving K57/27 	 K35/9.
Table 3. Glomerular staining following administration of anti-Fx1A
Group Injection Sheep IgG Rat C3c Rat C5b-9
A Anti-Fx1A 3.60.4 2.40.4 2.00.6
B Anti-Fx1A - anti-Crry 4.00.0 2.60.5 2.30.3
C Anti-Fx1A - anti-CD59 3.80.3 2.40.4 2.10.4
D Anti-Fx1A - anti-Crry - anti-CD59 3.80.3 2.40.4 2.20.3
Semiquantitative immunofluorescence scores for sheep IgG, rat C3c and C5b-9 are shown. There were no statistically significant differences between groups.
ing. The lower molecular weight of the F(ab)2 molecules
allows rapid access through the glomerular basement
membrane to the podocyte, but also leads to their being
quickly cleared [39]. Therefore, by IF, the sheep F(ab)2
antibodies were barely detectable in the glomerulus at
the time of sacrifice. Although staining for C3 was weak,
polyclonal anti-C3 antibodies only recognize epitopes on
the C3c portion of C3b; factor I quickly generates C3c,Fig. 4. Western blotting showing that affinity chromatography re-
leading to its disappearance within 24 hours of glomeru-moved anti-Crry and anti-CD59 reactivity from anti-Fx1A. rCrry and
rCD59 were run on separate gels. Each lane was incubated with either lar complement activation [37, 42]. Hence, staining for
control anti-Fx1A or anti-Fx1A depleted of anti-Crry and/or anti-CD59. C3c detects only freshly deposited C3b. Staining for C3d,
Preimmune sheep IgG was used as a negative control.
the fragment that remains bound to the site where com-
plement was activated, was of a higher intensity than
that for C3c, evidence that prior complement activation
had taken place.merular disease, including AHN. In these experiments,
It does seem likely that neutralization of CD59 oc-we evaluated the role of complement regulation in PHN.
curred after anti-CD59 F(ab)2 injection, thereby allowingIn the setting of megalin/anti-megalin immune deposits,
the formation of C5b-9 in those animals in which Crrysimultaneous neutralization of Crry and CD59 with anti-
was also inhibited. This is in spite of the absence ofCrry and anti-CD59 F(ab)2 resulted in significant pro-
staining for C5b-9, which may be due to insensitivityteinuria, demonstrating conclusively that normal com-
of the IF technique and/or the fact that podocytes canplement regulation can restrain complement-mediated
actively exocytose C5b-9 [40], which likely occurred priorglomerular injury. The amount of proteinuria was lower
to our harvest of kidney 42 hours after injection of anti-than that normally seen in PHN [41], consistent with
Crry and anti-CD59 F(ab)2. Overall, the developmentthe relatively small amounts of immune deposits in this
of proteinuria appears to be the most sensitive measureexperiment (Fig. 3A). Abnormal proteinuria did not oc-
of contemporaneous C5b-9–mediated podocyte injury.cur when Crry or CD59 alone was inhibited. Only when
These data showing that Crry and CD59 are importantboth were inhibited was the complement activation initi-
to limit anti-megalin-directed complement-mediated podo-ated by this modest amount of podocyte-associated IgG
cyte injury appear discrepant with events occurring withsufficient to lead to proteinuria. Interestingly, this result
Crry and CD59 neutralization by anti-Fx1A. We believeparallels data obtained in vitro with cultured glomerular
the difference lies in the quantity of glomerular-boundcells [25, 26].
IgG in the two models. The amount of glomerular IgGThe relative lack of staining for complement compo-
nents 42 hours after F(ab)2 antibody injection was surpris- remaining at sacrifice after anti-megalin antibody injec-
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Fig. 5. Urinary protein excretion in groups
receiving anti-Fx1A immunodepleted of anti-
Crry and/or anti-CD59. Each data point repre-
sents an individual animal. The short horizontal
bar represents the group mean. Proteinuria was
considered abnormal when 6 mg/day (hori-
zontal dashed line). Urinary protein was statis-
tically similar between all groups.
tion was relatively small (Fig. 3A), in contrast to the are passively administered a single dose of anti-Fx1A,
leading to the formation of significant subepithelial im-greater quantity and wider distribution of IgG observed
after anti-Fx1A administration (Fig. 6A). Since anti- mune deposits within several days [41]. Evidently, the
sudden antibody binding to the podocyte leads to aFx1A is a polyclonal antibody directed against a number
of different antigens, it is very effective at cross-linking, tempo of complement activation that cannot be restrained
by intrinsic complement regulators.allowing the persistence and accumulation of antibody-
antigen complexes. The amount of complement activa- The amount of proteinuria in our current work is con-
sistent with other studies, in which the proteinuria oftion initiated by the modest quantity of anti-megalin
monoclonal antibody deposits is held in check by Crry PHN is less than other proteinuric models [43]. We found
considerable variability in the amount of proteinuriaand CD59, while the large amount of IgG deposited
following anti-Fx1A administration activates sufficient within each group receiving anti-Fx1A, as noted by other
investigators [5]. Even rats with relatively low amountscomplement (as seen in Fig. 6) to exceed the capacity
of these complement regulators. We deliberately chose of proteinuria had strong staining for sheep IgG and rat
C3c and C5b-9, which has been noted in other studiesa dose of anti-Fx1A that was relatively low [41], to poten-
tially expose a difference between the groups, but even [44]. Thus, various factors beyond the amount of immune
deposit formation and complement activation influenceat this low dose, abnormal proteinuria was observed in
all the groups. As a model for events occurring in vivo, the extent of podocyte injury and proteinuria. A number
of explanations exist for these, including reactivity to-podocyte-bound IgG antibodies can overwhelm comple-
ment regulation in vitro as well [26]. wards other antigens [45, 46], or that factors such as
immune complex lipid oxidation [47–49], mononuclearThese data in the PHN model are in contrast to what
we have shown in the AHN model [28]. In AHN, anti- cell infiltration [50, 51], or hemodynamic alterations [1, 52]
play a role in causing functional injury and proteinuriabodies directed against Crry, either actively generated
or passively administered, are necessary for glomerular in PHN.
These studies highlight differences between the activecomplement activation and proteinuria to occur. Here
we show that passively administered anti-Fx1A causes and passive models of Heymann nephritis, showing that
complement regulatory proteins play an important rolean equivalent degree of proteinuria and glomerular com-
plement deposition after removal of anti-Crry antibod- in limiting complement activation by antibodies in sube-
pithelial immune deposits, but that they can be over-ies. Thus, it appears that normal glomerular complement
regulation by Crry is sufficient to limit antibody-directed whelmed when confronted with rapidly forming and ex-
tensive immune deposits. Providing exogenous solublecomplement-mediated damage in AHN but not in PHN.
In AHN, the immunized animal forms autoantibodies complement regulators or targeted site-specific comple-
ment inhibitors remain as promising therapies for mem-to Fx1A over a period of weeks, which deposit in the
glomerular subepithelial space over a similarly prolonged branous nephropathy and other human glomerular dis-
eases in which complement plays a pathogenic role.time course. In contrast, in the PHN model, animals
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